The comparative clinical efficacy of pyrophosphate/triclosan, copolymer/triclosan and zinc citrate/triclosan dentifrices for the reduction of supragingival calculus formation

K. J. Fairbrother, Michael Kowolik, M. E J Curzon, I. Muller, S. McKeown, C. M. Hill, C. Hannigan, R. D. Bartizek, D. J. White

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Three triclosan-containing 'multi-benefit' dentifrices were compared for clinical efficacy in reducing supragingival calculus formation following a dental prophylaxis. A total of 544 subjects completed a double-blind parallel-group clinical study using the Volpe-Manhold Index (VMI) to record severity and occurrence of supragingival calculus. The study design included a pre-test period where the calculus formation rate was measured in subjects brushing with a placebo dentifrice. Following a prophylaxis, subjects were stratified for age, gender and VMI scores and assigned to one of four treatments: 1) a dentifrice containing 5.0% soluble pyrophosphate/0.145% fluoride as NaF/silica abrasive/0.28% triclosan (hereafter PPi/TCS - comparable to Crest® Complete dentifrice, Procter and Gamble, UK); 2) a commercial dentifrice containing 2.0% Gantrez(TM) acid copolymer/0.145% fluoride as NaF/silica abrasive/0.30% triclosan (hereafter Gan/TCS - Colgate® Total dentifrice, Colgate-Palmolive Company, UK); 3) a commercial dentifrice containing 0.5% zinc citrate trihydrate/0.15% fluoride as sodium monofluorophosphate/silica abrasive/0.20% triclosan (hereafter Zn/TCS - Mentadent® P dentifrice, Unilever, UK); and 4) a control dentifrice comprised of 0.145% fluoride as NaF/silica abrasive (hereafter Control). Subjects were instructed to use their assigned dentifrice at least twice per day and to brush as they do normally. Supragingival calculus formation was assessed at two and four months using site-specific and whole-mouth VMI indices for both calculus severity and occurrence. Following four months of use, the PPi/TCS dentifrice provided statistically significant reductions in calculus severity (22-23%) and occurrence (15%) as compared with the Control dentifrice. The Zn/TCS dentifrice also provided significant reductions in calculus severity (17-19%) and occurrence (12-13%) as compared with the Control. The Gan/TCS produced no statistically significant reductions in calculus formation (occurrence or severity) compared with the Control. The PPi/TCS dentifrice provided statistically significant reductions in calculus severity (15-21%) and occurrence (12-16%) as compared with the Gan/TCS dentifrice. These results support the clinical effectiveness of PPi/TCS and Zn/TCS dentifrices for the reduction of supragingival dental calculus formation following a dental prophylaxis.

Original languageEnglish (US)
Pages (from-to)62-66
Number of pages5
JournalJournal of Clinical Dentistry
Volume8
Issue number2
StatePublished - 1997
Externally publishedYes

Fingerprint

Triclosan
Dentifrices
Calculi
Citric Acid
Zinc
Fluorides
Silicon Dioxide
Dental Prophylaxis
diphosphoric acid
fluorophosphate
Dental Calculus

ASJC Scopus subject areas

  • Dentistry(all)

Cite this

The comparative clinical efficacy of pyrophosphate/triclosan, copolymer/triclosan and zinc citrate/triclosan dentifrices for the reduction of supragingival calculus formation. / Fairbrother, K. J.; Kowolik, Michael; Curzon, M. E J; Muller, I.; McKeown, S.; Hill, C. M.; Hannigan, C.; Bartizek, R. D.; White, D. J.

In: Journal of Clinical Dentistry, Vol. 8, No. 2, 1997, p. 62-66.

Research output: Contribution to journalArticle

Fairbrother, K. J. ; Kowolik, Michael ; Curzon, M. E J ; Muller, I. ; McKeown, S. ; Hill, C. M. ; Hannigan, C. ; Bartizek, R. D. ; White, D. J. / The comparative clinical efficacy of pyrophosphate/triclosan, copolymer/triclosan and zinc citrate/triclosan dentifrices for the reduction of supragingival calculus formation. In: Journal of Clinical Dentistry. 1997 ; Vol. 8, No. 2. pp. 62-66.
@article{7e269b771f5f46ccb7085dbc70cf5760,
title = "The comparative clinical efficacy of pyrophosphate/triclosan, copolymer/triclosan and zinc citrate/triclosan dentifrices for the reduction of supragingival calculus formation",
abstract = "Three triclosan-containing 'multi-benefit' dentifrices were compared for clinical efficacy in reducing supragingival calculus formation following a dental prophylaxis. A total of 544 subjects completed a double-blind parallel-group clinical study using the Volpe-Manhold Index (VMI) to record severity and occurrence of supragingival calculus. The study design included a pre-test period where the calculus formation rate was measured in subjects brushing with a placebo dentifrice. Following a prophylaxis, subjects were stratified for age, gender and VMI scores and assigned to one of four treatments: 1) a dentifrice containing 5.0{\%} soluble pyrophosphate/0.145{\%} fluoride as NaF/silica abrasive/0.28{\%} triclosan (hereafter PPi/TCS - comparable to Crest{\circledR} Complete dentifrice, Procter and Gamble, UK); 2) a commercial dentifrice containing 2.0{\%} Gantrez(TM) acid copolymer/0.145{\%} fluoride as NaF/silica abrasive/0.30{\%} triclosan (hereafter Gan/TCS - Colgate{\circledR} Total dentifrice, Colgate-Palmolive Company, UK); 3) a commercial dentifrice containing 0.5{\%} zinc citrate trihydrate/0.15{\%} fluoride as sodium monofluorophosphate/silica abrasive/0.20{\%} triclosan (hereafter Zn/TCS - Mentadent{\circledR} P dentifrice, Unilever, UK); and 4) a control dentifrice comprised of 0.145{\%} fluoride as NaF/silica abrasive (hereafter Control). Subjects were instructed to use their assigned dentifrice at least twice per day and to brush as they do normally. Supragingival calculus formation was assessed at two and four months using site-specific and whole-mouth VMI indices for both calculus severity and occurrence. Following four months of use, the PPi/TCS dentifrice provided statistically significant reductions in calculus severity (22-23{\%}) and occurrence (15{\%}) as compared with the Control dentifrice. The Zn/TCS dentifrice also provided significant reductions in calculus severity (17-19{\%}) and occurrence (12-13{\%}) as compared with the Control. The Gan/TCS produced no statistically significant reductions in calculus formation (occurrence or severity) compared with the Control. The PPi/TCS dentifrice provided statistically significant reductions in calculus severity (15-21{\%}) and occurrence (12-16{\%}) as compared with the Gan/TCS dentifrice. These results support the clinical effectiveness of PPi/TCS and Zn/TCS dentifrices for the reduction of supragingival dental calculus formation following a dental prophylaxis.",
author = "Fairbrother, {K. J.} and Michael Kowolik and Curzon, {M. E J} and I. Muller and S. McKeown and Hill, {C. M.} and C. Hannigan and Bartizek, {R. D.} and White, {D. J.}",
year = "1997",
language = "English (US)",
volume = "8",
pages = "62--66",
journal = "Journal of Clinical Dentistry",
issn = "0895-8831",
publisher = "Professional Audience Communications Inc.",
number = "2",

}

TY - JOUR

T1 - The comparative clinical efficacy of pyrophosphate/triclosan, copolymer/triclosan and zinc citrate/triclosan dentifrices for the reduction of supragingival calculus formation

AU - Fairbrother, K. J.

AU - Kowolik, Michael

AU - Curzon, M. E J

AU - Muller, I.

AU - McKeown, S.

AU - Hill, C. M.

AU - Hannigan, C.

AU - Bartizek, R. D.

AU - White, D. J.

PY - 1997

Y1 - 1997

N2 - Three triclosan-containing 'multi-benefit' dentifrices were compared for clinical efficacy in reducing supragingival calculus formation following a dental prophylaxis. A total of 544 subjects completed a double-blind parallel-group clinical study using the Volpe-Manhold Index (VMI) to record severity and occurrence of supragingival calculus. The study design included a pre-test period where the calculus formation rate was measured in subjects brushing with a placebo dentifrice. Following a prophylaxis, subjects were stratified for age, gender and VMI scores and assigned to one of four treatments: 1) a dentifrice containing 5.0% soluble pyrophosphate/0.145% fluoride as NaF/silica abrasive/0.28% triclosan (hereafter PPi/TCS - comparable to Crest® Complete dentifrice, Procter and Gamble, UK); 2) a commercial dentifrice containing 2.0% Gantrez(TM) acid copolymer/0.145% fluoride as NaF/silica abrasive/0.30% triclosan (hereafter Gan/TCS - Colgate® Total dentifrice, Colgate-Palmolive Company, UK); 3) a commercial dentifrice containing 0.5% zinc citrate trihydrate/0.15% fluoride as sodium monofluorophosphate/silica abrasive/0.20% triclosan (hereafter Zn/TCS - Mentadent® P dentifrice, Unilever, UK); and 4) a control dentifrice comprised of 0.145% fluoride as NaF/silica abrasive (hereafter Control). Subjects were instructed to use their assigned dentifrice at least twice per day and to brush as they do normally. Supragingival calculus formation was assessed at two and four months using site-specific and whole-mouth VMI indices for both calculus severity and occurrence. Following four months of use, the PPi/TCS dentifrice provided statistically significant reductions in calculus severity (22-23%) and occurrence (15%) as compared with the Control dentifrice. The Zn/TCS dentifrice also provided significant reductions in calculus severity (17-19%) and occurrence (12-13%) as compared with the Control. The Gan/TCS produced no statistically significant reductions in calculus formation (occurrence or severity) compared with the Control. The PPi/TCS dentifrice provided statistically significant reductions in calculus severity (15-21%) and occurrence (12-16%) as compared with the Gan/TCS dentifrice. These results support the clinical effectiveness of PPi/TCS and Zn/TCS dentifrices for the reduction of supragingival dental calculus formation following a dental prophylaxis.

AB - Three triclosan-containing 'multi-benefit' dentifrices were compared for clinical efficacy in reducing supragingival calculus formation following a dental prophylaxis. A total of 544 subjects completed a double-blind parallel-group clinical study using the Volpe-Manhold Index (VMI) to record severity and occurrence of supragingival calculus. The study design included a pre-test period where the calculus formation rate was measured in subjects brushing with a placebo dentifrice. Following a prophylaxis, subjects were stratified for age, gender and VMI scores and assigned to one of four treatments: 1) a dentifrice containing 5.0% soluble pyrophosphate/0.145% fluoride as NaF/silica abrasive/0.28% triclosan (hereafter PPi/TCS - comparable to Crest® Complete dentifrice, Procter and Gamble, UK); 2) a commercial dentifrice containing 2.0% Gantrez(TM) acid copolymer/0.145% fluoride as NaF/silica abrasive/0.30% triclosan (hereafter Gan/TCS - Colgate® Total dentifrice, Colgate-Palmolive Company, UK); 3) a commercial dentifrice containing 0.5% zinc citrate trihydrate/0.15% fluoride as sodium monofluorophosphate/silica abrasive/0.20% triclosan (hereafter Zn/TCS - Mentadent® P dentifrice, Unilever, UK); and 4) a control dentifrice comprised of 0.145% fluoride as NaF/silica abrasive (hereafter Control). Subjects were instructed to use their assigned dentifrice at least twice per day and to brush as they do normally. Supragingival calculus formation was assessed at two and four months using site-specific and whole-mouth VMI indices for both calculus severity and occurrence. Following four months of use, the PPi/TCS dentifrice provided statistically significant reductions in calculus severity (22-23%) and occurrence (15%) as compared with the Control dentifrice. The Zn/TCS dentifrice also provided significant reductions in calculus severity (17-19%) and occurrence (12-13%) as compared with the Control. The Gan/TCS produced no statistically significant reductions in calculus formation (occurrence or severity) compared with the Control. The PPi/TCS dentifrice provided statistically significant reductions in calculus severity (15-21%) and occurrence (12-16%) as compared with the Gan/TCS dentifrice. These results support the clinical effectiveness of PPi/TCS and Zn/TCS dentifrices for the reduction of supragingival dental calculus formation following a dental prophylaxis.

UR - http://www.scopus.com/inward/record.url?scp=0030945249&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030945249&partnerID=8YFLogxK

M3 - Article

VL - 8

SP - 62

EP - 66

JO - Journal of Clinical Dentistry

JF - Journal of Clinical Dentistry

SN - 0895-8831

IS - 2

ER -